A AutoLab
Equities / Hims & Hers Health Inc (NYSE: HIMS)

Hims & Hers Health Inc

Fastest-scaling DTC consumer-health platform; GLP-1 reset masks platform optionality the market is mispricing

NYSE: HIMS Consumer Health / Telehealth United States 2026-05-29 0.58MODERATE
Download PDF Infographic (PNG)

Snapshot

  • Ticker: NYSE: HIMS
  • Price (2026-05-28): ~$24.50 (52-wk range $13.75 – $70.42) [S1]
  • Market cap: ~$5.83B [S1]
  • Revenue: FY2023 $872M · FY2024 $1,477M · FY2025 $2,348M [S2][S3][S4]
  • Growth (YoY): FY24 +69% · FY25 +59% · FY26 guide +19–28% ($2.8–3.0B) [S2][S3][S4][S5]
  • Profitability (GAAP): FY23 −$23.5M · FY24 +$126.0M · FY25 +$128.4M; Adj. EBITDA FY25 $318M (~13.5%) [S2][S3][S4]
  • Q1 2026 (latest): Revenue $608M (+4% YoY), net loss −$92.1M, Adj. EBITDA $44.3M, GM 65% (vs 73%) — compounded-GLP-1 wind-down inventory & restructuring write-off $33M [S5][S6]
  • FCF: Operating cash flow FY25 $52.8M (capex compressed FCF; specifics undisclosed) [S4]
  • Net cash/debt: $228.6M cash + $348.9M ST investments = ~$578M liquidity vs $1.0B 0% convertible notes due 2030 → ~$420M net debt (notes are 0%-coupon, dilution-priced) [S4][S7]
  • Valuation: EV ~$6.25B → EV/Sales (FY25) ~2.7x; EV/Sales (FY26E mid) ~2.2x; EV/Adj.EBITDA (FY25) ~20x; EV/Adj.EBITDA (FY26E mid $312M) ~20x; P/E undefined on Q1 26 loss (TTM P/E ~50x on FY25 GAAP NI) [S1][S4][S5]
  • Currency: USD
  • Geography: US ~95%+ of FY25 revenue; international (UK/EU/Canada) launched 2025 via Zava/Medici/Livewell acquisitions — Q1 26 international revenue $78.2M (+969% YoY), ~13% of mix and rising; Eucalyptus deal (mid-2026 close) adds AU/JP and deepens UK/DE/CA [S4][S5][S8][S9]
  • What: Direct-to-consumer subscription telehealth platform — async clinician access + owned 503A/503B pharmacy fulfillment + AI-driven personalization across sexual health, hair, derm, mental health, weight loss
  • Value-chain position: Last-mile consumer access layer between pharma manufacturers (Novo, Lilly, generic compounders) and ~2.6M subscribers; owns telehealth + clinician network + fulfillment but not the molecules
  • End markets: US adult consumer health — ED/hair (legacy core), GLP-1 weight loss (2024–25 growth engine), derm, mental health, testosterone, menopause, longevity (in launch)
  • Founded / HQ: 2017 / San Francisco, CA
  • CEO: Andrew Dudum (co-founder; Class V supervoting share ≈ 87.7% voting power)
  • Top competitors: Ro/Roman (private, $598M ARR), LifeMD, Amazon One Medical + Pharmacy (Foundayo $149/mo, Wegovy/Zepbound $299/mo cash launched Apr 2026), LillyDirect, Cost Plus Drugs, Henry Meds, traditional pharmacy chains
  • Key partners/customers: Novo Nordisk (Mar 2026 deal — Ozempic, Wegovy injectables + Wegovy oral) [S10][S11]; Eli Lilly (Apr 2026 expansion — Zepbound vials/KwikPen, Foundayo via LillyDirect self-pay) [S12]; consumer subscribers ~2.6M (Q1 26)
  • Catalyst: Branded-GLP-1 ramp through Novo/Lilly bundles + Eucalyptus closing mid-2026 = first quarter where global, branded, multi-specialty platform thesis is testable in audited numbers (Q3/Q4 2026).
  • Verdict: Post-GLP-1-compounding reset is creating a multi-quarter optics gap between consensus (decel narrative) and platform reality (ex-GLP-1 subs +9% with international and specialty surface expanding) — asymmetric setup if the 2030 $6.5B/$1.3B EBITDA framework lands within 18 months of trajectory.
  • Confidence: 0.58

The asymmetric thesis

The market is treating HIMS as a one-trick GLP-1 compounder caught by FDA enforcement — the stock is down ~65% from its $70 high on exactly that story [S1] — but the underlying business has quietly become the only DTC consumer-health platform to clear $2B in revenue with GAAP profitability and a 2.6M-subscriber recurring base [S4]. The “pre-trend” bet is that 2026 is the trough year of a forced transition (compounded → branded GLP-1, US-only → global, single-specialty → multi-specialty) and that consensus has not yet modeled what a $6.5B / $1.3B EBITDA 2030 platform [S13] looks like across (a) Novo+Lilly branded GLP-1 cash-pay channel, (b) ~775K Eucalyptus customers in AU/UK/EU/CA/JP closing mid-2026 [S8], (c) new specialties (testosterone, menopause, longevity, sleep) launching from a brand with 75% direct/organic traffic [hims-hers-moat-may9.md]. Path to 3–10×: if 2030 targets land — implying ~22% revenue CAGR from FY25 with 20% Adj. EBITDA margin — the stock would re-rate at 15× $1.3B EBITDA = ~$20B EV, ~3.4× from here; a “platform” multiple (25–30×) on outperformance plus international and longevity optionality gets to ~5–7×. The optionality the market is ignoring is that HIMS is becoming the consumer access layer for branded pharma’s cash-pay GLP-1 channel at the exact moment the GLP-1 TAM is on a $30B → $95–190B trajectory [S14][S15] — pharma needs a DTC interface, and post the March 2026 Novo deal and April 2026 Lilly expansion, HIMS is demonstrably it.

Financials

USD millionsFY2023FY2024FY2025
Revenue8721,4772,348
YoY growth+65%+69%+59%
Gross margin~82%~79%~74%
Adj. EBITDA~50177318
Adj. EBITDA margin~6%~12%~13.5%
GAAP operating incomen/m~62106
GAAP net income−23.5126.0128.4
Operating cash flow~73~20952.8
Cash + ST investments~97~300577
Convertible notes (0% 2030)——1,000
Subscribers (M, end of period)1.52.22.5

Sources: [S2][S3][S4]. FY25 OCF compressed by working-capital build for Novo branded inventory + Eucalyptus deal costs. Q1 2026 standalone: Revenue $608M (+4%), Adj. EBITDA $44.3M, GAAP NI −$92.1M (includes $33M compounded-GLP-1 restructuring), subs 2.6M (+9% YoY), international $78M (+969%) [S5][S6].

Sector / TAM

  • US DTC telehealth services: $1.47B (2023) → $9.53B (2030E), ~30.3% CAGR [S16]. HIMS at ~$2.35B FY25 already exceeds the 2030 sized market — i.e., DTC telehealth is no longer a “sector,” HIMS is in the process of defining it, with global expansion adding the second-leg TAM.
  • Global telehealth (broader): $123B (2024) → $455B (2030E), ~25% CAGR [S16].
  • GLP-1 obesity drug market: $30B (2025) → $48–95B (2030E) per Grand View / Goldman Sachs forecasts; Morgan Stanley sees $190B by 2035 [S14][S15]. ~12–15M US patients projected on GLP-1s by 2030 vs ~110M US adults clinically obese — meaningful headroom; cash-pay channel currently ~30–40% of branded volume given insurance gaps, which is HIMS’s swim lane.
  • HIMS-stated 2030 ambition: ≥$6.5B revenue and ≥$1.3B Adj. EBITDA [S13] — implies ~22% revenue CAGR FY25→FY30 and 20% margin (vs 13.5% FY25). Confidence in this is the entire bet.

Recent news (last 12 months)

What would change the view

Specific, falsifiable signals over the next 18 months. Both directions.

  • (+) FY2026 Adj. EBITDA lands at the upper end of the $275–350M guide AND international revenue tracks above $400m for the year — confirms the platform + geo-extension narrative.
  • (+) HIMS discloses same-category, ex-GLP-1 cohort retention >55% at 12 months on at least two categories — validates the platform/moat framing the bear case tests.
  • (+) Founder Dudum makes >$10m of open-market purchases — materially resets the insider-alignment concern.
  • (−) Q3/Q4 2026 subscriber net adds fall below +50K for two consecutive quarters — confirms the Q1 2026 +40K print as the new normal.
  • (−) HHS DOJ referral results in a consent decree or marketing-claim cap — re-prices the platform on regulatory + SBC dilution risk.
  • (−) Branded-GLP-1 cash-pay take-rate visibly compressed by Amazon/Ro/LillyDirect pricing within two quarters — the channel-shift bull case loses its central data point.

Bull case

  1. The platform is monetizing the right side of the GLP-1 wave, not the wrong side. Pre-FDA-crackdown bears were right that compounded sema was structurally dead. Post the March 2026 Novo + April 2026 Lilly deals, HIMS is the only multi-pharma cash-pay DTC channel with both Novo (Wegovy oral, Ozempic) and Lilly (Zepbound, Foundayo) at scale — pharma chose them as the consumer access layer twice in 60 days [S10][S12]. With the GLP-1 TAM tracking to $95B+ by 2030 and cash-pay being ~30–40% of branded volume due to insurance gaps [S14][S15], even single-digit channel share on branded is materially larger than the compounded P&L it replaces.
  2. International + multi-specialty optionality is barely modeled. Q1 2026 international revenue +969% YoY to $78M [S5]; Eucalyptus closes mid-2026 adding 775K subscribers across AU/UK/DE/CA/JP at a $240M upfront price ($310/customer) [S8] — i.e., HIMS is acquiring international DTC infrastructure for less than a single quarter of US ad spend. Layer on testosterone, menopause, longevity, sleep specialty launches into a brand with 75% direct/organic traffic [moat note], and the 2030 $6.5B target needs only ~22% CAGR — well below FY24/FY25 actuals.
  3. Liquidity, cost base, and balance sheet survived the reset. $577M cash + ST investments [S4] against $1.0B 0%-coupon convertible due 2030 [S7] means net debt is artificially low and there is no maturity wall. The Q1 26 net loss is restructuring-driven, not operating-driven — Adj. EBITDA stayed positive ($44M) through the GLP-1 mix cliff. Marketing as % of revenue compressed 51% (FY23) → 39% (FY25) with implied gross-add CAC down ~24% YoY [moat note] — operating leverage is showing up, in the worst possible competitive year.

Bear case

  1. The 2030 target needs platform mechanics that have not been audited. Consensus FY26 mid is +24% growth — a sharp decel from +59%. If the same-category, ex-GLP-1 cohort retention curves (which HIMS still does not disclose by vintage/category) are at literature floors (~30–50% 12-mo for finasteride; ~30% for PDE5 inhibitors; ~33% for SSRIs [moat note]), the unit economics cannot support $6.5B / $1.3B by 2030. The Q1 26 +4% revenue print and 65% GM compression are the first audited datapoints consistent with a more normal DTC subscription business, not a moat-grade platform.
  2. Competitive entry has fully materialized at lower price points. Amazon One Medical launched ED/hair/derm at $10–19/mo (Nov 2024) and full GLP-1 program at $149 Foundayo / $299 Wegovy cash (Apr 2026); Ro is offering 50%-off GLP-1 pricing ($39 first month vs HIMS $149); LillyDirect captured ~45% of obesity-drug volume engaging 1M+ patients in 2025 [moat note]. HIMS has not exercised list-price pricing power against any of these, and Q4 25 / Q1 26 subscriber net adds decelerated sharply (+182K → +40K Q4 YoY) [moat note]. Pharma can also disintermediate HIMS by directing branded volume to its own DTC portals.
  3. Capital structure and governance create founder-exit asymmetry. CEO Dudum holds Class V supervoting (~87.7% voting power) while Class A economic dispositions ran ~$48–70M in 2024–25 with zero open-market insider purchases across 24 months — including after the Feb 26 FDA action and ~14% gap-down [moat note]. SBC at fully-burdened FY25 ~$200–230M wipes out the $128M GAAP NI; the 0% convertible due 2030 ($1.0B principal) is a non-amortizing dilution time-bomb if the equity is below conversion at maturity. The HHS DOJ referral remains unresolved.

Sources